Franklin Street Advisors Inc Nc buys $10,407,243 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Franklin Street Advisors Inc Nc scooped up 2,666 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 5, 2016. The investment management firm now holds a total of 164,178 shares of AbbVie Inc which is valued at $10,407,243.AbbVie Inc makes up approximately 1.91% of Franklin Street Advisors Inc Nc’s portfolio.

Other Hedge Funds, Including , Eqis Capital Management reduced its stake in ABBV by selling 3,219 shares or 25.4% in the most recent quarter. The Hedge Fund company now holds 9,452 shares of ABBV which is valued at $599,162. AbbVie Inc makes up approx 0.04% of Eqis Capital Management’s portfolio.Washington Trust Bank reduced its stake in ABBV by selling 135 shares or 0.25% in the most recent quarter. The Hedge Fund company now holds 54,640 shares of ABBV which is valued at $3,463,630. AbbVie Inc makes up approx 0.83% of Washington Trust Bank’s portfolio. Harbour Capital Advisors sold out all of its stake in ABBV during the most recent quarter. The investment firm sold 6,447 shares of ABBV which is valued $408,675.Lau Associates reduced its stake in ABBV by selling 400 shares or 6.38% in the most recent quarter. The Hedge Fund company now holds 5,873 shares of ABBV which is valued at $372,289. AbbVie Inc makes up approx 0.38% of Lau Associates’s portfolio.

AbbVie Inc closed down -0.23 points or -0.36% at $63 with 47,19,437 shares getting traded on Tuesday. Post opening the session at $63.31, the shares hit an intraday low of $62.55 and an intraday high of $63.53 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Investors should note that on Sep 9, 2016, AbbVie Inc announced a cash dividend of $0.5700. The company’s management has announced Oct 12, 2016 as the ex-dividend date and fixed the record date on Oct 14, 2016. The payable date has been fixed on Nov 15, 2016.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by JP Morgan to ” Neutral” on Sep 8, 2016. Raymond James Initiated AbbVie Inc on Sep 2, 2016 to “Outperform”, Price Target of the shares are set at $82.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.